Clinical trial
Gene therapy trial for the treatment of X-linked retinitis pigmentosa associated with variants in the RPGR Gene
Gene therapy trial for the treatment of X-linked retinitis pigmentosa associated with variants in the RPGR Gene
| Trial Fact Box | |
|---|---|
| NCT Code | NCT04671433 |
| Sponsor | Janssen Research & Development, LLC |
| Study type(s) |
Interventional
|
| Phase | Phase 3 |
| Enrollment (Actual) | 105 |
| Study Start (Actual) | 4 December 2020 |
| Primary Completion (Estimated) | 30 September 2024 |
| Study Completion (Estimated) | 30 September 2024 |
Official Title:
Phase 3 Randomized, Controlled Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene
Brief Summary:
A clinical trial of AAV5-RPGR vector for participants with X-linked retinitis pigmentosa (XLRP)
View full details